Retrospective study reveals that time to recurrence significantly impacts survival in recurrent head and neck cancer, highlighting its potential role in clinical trial stratification.
TTRI significantly influenced the survival, while recurrence patterns did not. In our study, the retrospective design limited our ability to definitively establish whether early recurrent R/M-HNSCC patients would benefit more from platinum-doublet. Despite poor prognosis, early recurrent patients benefited from 1L systemic treatments. Given the variation in prognoses, TTRI should be considered a stratification factor in future clinical trials.
No takes yet. Share an insight, caveat, or question.
Pitakpaiboonkul et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: